Drugs / meso-CART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02706782 | Mar 2016 → Feb 2018 | malignant pancreatic neoplasm | Shanghai GeneChem Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03182803 | Jun 2017 → Jan 2019 | neoplasm | Shanghai Cell Therapy Research Institute | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | meso-CAR-T | “This study is being conducted to assess vascular interventional therapy mediated anti-mesothelin-CAR-T(meso-CAR-T) cells safety and efficacy in treating patients with advanced...” NCT02706782 ↗ |
| Known as | anti-mesothelin-CAR-T | “This study is being conducted to assess vascular interventional therapy mediated anti-mesothelin-CAR-T(meso-CAR-T) cells safety and efficacy in treating patients with advanced...” NCT02706782 ↗ |
| Action | Deplete | “MesoCAR-T can specificly and effectively kill the mesothelin positive cancer cells” NCT03182803 ↗ |
| Modality | Cell therapy | “CAR-T cells” NCT02706782 ↗ |
| Route | Other | “The infusion way is vascular interventional mediated” NCT02706782 ↗ |